Biotech Stocks: Opus Genetics and the Riskiest Investments with Over 300% Upside

Opus Genetics, a clinical-stage biotech company, is one of the riskiest bets investors are making with a valuation of $1.4 billion. The company focuses on developing gene therapies for inherited retinal diseases and has surged 60.3% year-to-date. Its stock hinges on clinical success, regulatory outcomes, and ongoing funding. Opus Genetics has completed a successful FDA RMAT meeting for its OPGx-LCA5 gene therapy and recently raised $23 million through an equity offering, bringing total liquidity to over $50 million.